𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interpreting the results of Parkinson's disease clinical trials: Time for a change

✍ Scribed by Nick H. G. Holford; John G. Nutt

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
199 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Randomized clinical trials testing putative disease‐modifying agents in Parkinson's disease (PD) have yielded controversial results that have not influenced evidence‐based recommendations for the treatment of PD. We argue that the failure of these clinical trials may be linked to end point‐based statistical analyses that must make prior assumptions about the magnitude and the time course of wash‐in and wash‐out of drug effects. Many of these shortcomings may be avoided with quantitative modeling of the entire time course of the clinical trial and examining evidence for three concomitant processes, disease progression, symptomatic drug effects and disease modifying effects. The power of this approach is illustrated by modeling of DATATOP and ELLDOPA trial data. © 2010 Movement Disorder Society

📜 SIMILAR VOLUMES

A recommended scale for cognitive screen
A recommended scale for cognitive screening in clinical trials of Parkinson's disease
✍ Kelvin L. Chou; Melissa M. Amick; Jason Brandt; Richard Camicioli; Karen Frei; D 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Abstract Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to

Test–Retest reliability of the Unified P
Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial
✍ Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Our objective was to assess the test-retest reliability of the Unified Parkinson's Disease Rating Scale (UPDRS). The UPDRS is the most widely used instrument for measuring severity of parkinsonian symptoms in clinical research and in practice. The validity and inter-rater reliability of this scale h

The ADAS-cog and clinically meaningful c
The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease
✍ Kenneth Rockwood; Sherri Fay; Mary Gorman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

## Abstract ## Background A minimum 4‐point change at 6 months on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐cog) is deemed clinically important, but this cut‐point has been little studied in relation to clinical meaningfulness. In an investigator‐initiated, clinical trial o

A comparison of treatment thresholds in
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
✍ Connie Marras; Anthony E. Lang; Shirley W. Eberly; David Oakes; Stanley Fahn; St 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) and Parkinson Research Examination of CEP‐1347 Trial (PRECEPT) were two clinical trials of potential disease‐modifying agents for Parkinson's disease that used the time to reaching disability sufficient to require d

Cancer incidence in a trial of an antiap
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
✍ Steven R. Schwid; Janice Bausch; David Oakes; Lynn Schuchter; Caroline Tanner; M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in